227 related articles for article (PubMed ID: 26784938)
1. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
Cho SK; Chung JY
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
[TBL] [Abstract][Full Text] [Related]
2. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE; Verstuyft C; Kroemer HK; Becquemont L; Kim RB
Am J Physiol Renal Physiol; 2010 Apr; 298(4):F997-F1005. PubMed ID: 20053795
[TBL] [Abstract][Full Text] [Related]
3. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
4. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.
Christensen MM; Pedersen RS; Stage TB; Brasch-Andersen C; Nielsen F; Damkier P; Beck-Nielsen H; Brøsen K
Pharmacogenet Genomics; 2013 Oct; 23(10):526-34. PubMed ID: 23873119
[TBL] [Abstract][Full Text] [Related]
5. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
[TBL] [Abstract][Full Text] [Related]
6. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
7. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
8. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
9. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy Increases the Renal Secretion of N
Bergagnini-Kolev MC; Hebert MF; Easterling TR; Lin YS
Drug Metab Dispos; 2017 Mar; 45(3):325-329. PubMed ID: 28069720
[TBL] [Abstract][Full Text] [Related]
11. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
Müller F; König J; Hoier E; Mandery K; Fromm MF
Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
[TBL] [Abstract][Full Text] [Related]
12. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
[TBL] [Abstract][Full Text] [Related]
13. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
[TBL] [Abstract][Full Text] [Related]
14. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.
Wang ZJ; Yin OQ; Tomlinson B; Chow MS
Pharmacogenet Genomics; 2008 Jul; 18(7):637-45. PubMed ID: 18551044
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
16. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
17. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin.
Tsuda M; Terada T; Mizuno T; Katsura T; Shimakura J; Inui K
Mol Pharmacol; 2009 Jun; 75(6):1280-6. PubMed ID: 19332510
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809
[TBL] [Abstract][Full Text] [Related]
20. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
